121 related articles for article (PubMed ID: 29748211)
21. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
22. Generation and characterization of bioluminescent xenograft mouse models of MLL-related acute leukemias and in vivo evaluation of luciferase-targeting siRNA nanoparticles.
Fazzina R; Lombardini L; Mezzanotte L; Roda A; Hrelia P; Pession A; Tonelli R
Int J Oncol; 2012 Aug; 41(2):621-8. PubMed ID: 22665135
[TBL] [Abstract][Full Text] [Related]
23. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
24. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221.
Kotani A; Ha D; Hsieh J; Rao PK; Schotte D; den Boer ML; Armstrong SA; Lodish HF
Blood; 2009 Nov; 114(19):4169-78. PubMed ID: 19749093
[TBL] [Abstract][Full Text] [Related]
25. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
Spijkers-Hagelstein JA; Pinhanços SS; Schneider P; Pieters R; Stam RW
Leukemia; 2014 Apr; 28(4):761-9. PubMed ID: 23958920
[TBL] [Abstract][Full Text] [Related]
26. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
[TBL] [Abstract][Full Text] [Related]
27. The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia.
Dobbins SE; Sherborne AL; Ma YP; Bardini M; Biondi A; Cazzaniga G; Lloyd A; Chubb D; Greaves MF; Houlston RS
Genes Chromosomes Cancer; 2013 Oct; 52(10):954-60. PubMed ID: 23893660
[TBL] [Abstract][Full Text] [Related]
28. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of S100A6 induces GVL effects in MLL/AF4-positive ALL in human PBMC-SCID mice.
Tamai H; Miyake K; Yamaguchi H; Shimada T; Dan K; Inokuchi K
Bone Marrow Transplant; 2014 May; 49(5):699-703. PubMed ID: 24583627
[TBL] [Abstract][Full Text] [Related]
30. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
31. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
32. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
33. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung M; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ
Oncogene; 2019 May; 38(20):3824-3842. PubMed ID: 30670779
[TBL] [Abstract][Full Text] [Related]
34. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
35. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.
Somers K; Chudakova DA; Middlemiss SM; Wen VW; Clifton M; Kwek A; Liu B; Mayoh C; Bongers A; Karsa M; Pan S; Cruikshank S; Scandlyn M; Hoang W; Imamura T; Kees UR; Gudkov AV; Chernova OB; Haber M; Norris MD; Henderson MJ
Oncotarget; 2016 Jul; 7(29):46067-46087. PubMed ID: 27317766
[TBL] [Abstract][Full Text] [Related]
36. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
Cruickshank MN; Ford J; Cheung LC; Heng J; Singh S; Wells J; Failes TW; Arndt GM; Smithers N; Prinjha RK; Anderson D; Carter KW; Gout AM; Lassmann T; O'Reilly J; Cole CH; Kotecha RS; Kees UR
Leukemia; 2017 Jan; 31(1):40-50. PubMed ID: 27443263
[TBL] [Abstract][Full Text] [Related]
37. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
38. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
Prange KHM; Mandoli A; Kuznetsova T; Wang SY; Sotoca AM; Marneth AE; van der Reijden BA; Stunnenberg HG; Martens JHA
Oncogene; 2017 Jun; 36(23):3346-3356. PubMed ID: 28114278
[TBL] [Abstract][Full Text] [Related]
39. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
Stumpel DJ; Schotte D; Lange-Turenhout EA; Schneider P; Seslija L; de Menezes RX; Marquez VE; Pieters R; den Boer ML; Stam RW
Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
[TBL] [Abstract][Full Text] [Related]
40. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells.
Accordi B; Galla L; Milani G; Curtarello M; Serafin V; Lissandron V; Viola G; te Kronnie G; De Maria R; Petricoin EF; Liotta LA; Indraccolo S; Basso G
Leukemia; 2013 Apr; 27(5):1019-27. PubMed ID: 23228943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]